Bone drug trial aims to stop precancer from turning into cancer
NCT ID NCT03839459
Summary
This study tested whether denosumab, a medication that strengthens bones, could reduce the risk of smoldering multiple myeloma progressing to active multiple myeloma. Twenty patients with this precancerous condition received monthly injections for one year. Researchers monitored whether their risk category improved and tracked if they developed active cancer over two years of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Rochester
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.